GSK (LON:GSK) Posts Earnings Results

GSK (LON:GSK) issued its quarterly earnings results on Wednesday. The company reported GBX 23.20 ($0.29) earnings per share (EPS) for the quarter, Digital Look Earnings reports. GSK had a return on equity of 33.30% and a net margin of 12.83%.

GSK Price Performance

GSK stock traded up GBX 103.50 ($1.29) during midday trading on Wednesday, reaching GBX 1,483.50 ($18.52). The company’s stock had a trading volume of 72,538,188 shares, compared to its average volume of 33,660,703. The company has a debt-to-equity ratio of 123.04, a quick ratio of 0.73 and a current ratio of 0.82. GSK has a fifty-two week low of GBX 1,282.50 ($16.01) and a fifty-two week high of GBX 1,823.50 ($22.76). The firm has a market capitalization of £60.53 billion, a PE ratio of 1,312.83, a P/E/G ratio of 1.24 and a beta of 0.31. The stock’s 50 day simple moving average is GBX 1,351.15 and its 200 day simple moving average is GBX 1,457.70.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on GSK shares. Berenberg Bank dropped their target price on GSK from GBX 1,820 ($22.72) to GBX 1,600 ($19.97) and set a “buy” rating on the stock in a report on Friday, November 29th. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of GSK in a research report on Tuesday, January 7th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. According to MarketBeat.com, GSK has an average rating of “Moderate Buy” and a consensus target price of GBX 1,805.83 ($22.54).

Insider Transactions at GSK

In related news, insider Jonathan Symonds purchased 1,500 shares of GSK stock in a transaction dated Friday, December 20th. The stock was bought at an average cost of GBX 1,315 ($16.41) per share, for a total transaction of £19,725 ($24,619.32). Corporate insiders own 1.61% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.